PLOS MEDICINE by Mark J. Siedner, Lawrence O. Gostin, Hilarie H. Cranmer,and John D. Kraemer                        March 24, 2015

In-depth paper on lessons learned from the West Africa Ebola outbreak

NEW YORK TIMES  by Sheri Fink                                                            March  25, 2015

Worries have widened in recent days over the number of people in Liberia who may have been exposed to the country’s first Ebola case in more than two weeks, a street vendor who lived in a one-bathroom house shared with 52 others in a Monrovia suburb and who had sold food at a school where more than 1,900 students are enrolled.

A new study shows the durability of a novel 'disseminating' cytomegalovirus (CMV)-based Ebola virus (Zaire ebolavirus; EBOV) vaccine strategy that may eventually have the potential to reduce ebolavirus infection in wild African ape species.

These are western lowland gorillas, one of the great ape species threatened by Ebola. Credit: Copyright 2012 Chris Whittier

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

The multi-institutional study is led by Dr Michael Jarvis at Plymouth University, and is published today, 25th March 2015, in Vaccine.

africansuntimes.com - by Mardia Stone, M.D. - March 23, 2015

On March 20^th, a newly confirmed Ebola case was reported [in Liberia] . . . This time, sexual contact is presumed to be the hidden culprit in this new Ebola virus transmission, according to a statement from the Ministry of Information and case reports from the National Ebola Response Team.

The story goes like this. . . .

(READ COMPLETE ARTICLE - PLEASE ALLOW ADDITIONAL TIME FOR POSSIBLE SLOW-LOADING SITE)

(ALSO SEE RELATED INFORMATION HERE)